Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhalational Anesthetics: Overview01:20

Inhalational Anesthetics: Overview

357
Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
357
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

232
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
232
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

169
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
169
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

285
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
285
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

179
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
179
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

1.6K
In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Reply to Dr Iserson.

Wilderness & environmental medicine·2026
Same author

Infectious disease outcomes of NASA's health stabilization program.

NPJ microgravity·2026
Same author

United States Aeromedical Evacuations from Antarctica from 2015 to 2023: A Retrospective Analysis of Military and Civilian Data.

Wilderness & environmental medicine·2026
Same author

Spacecraft Maximum Allowable Concentrations for 1-Propanol.

Aerospace medicine and human performance·2025
Same author

Generation of enzyme-converted type O whole blood from type A whole blood: A translational study using swine whole blood.

Transfusion·2025
Same author

An outbreak of poisoning in Vietnam caused by the adulteration of alcoholic drinks with acetonitrile.

Clinical toxicology (Philadelphia, Pa.)·2025
Same journal

Incidental Renal Cell Carcinoma in an Active-Duty Fighter Pilot.

Aerospace medicine and human performance·2026
Same journal

Large Language Models as Behavioral Health Teammates in Long-Duration Spaceflight.

Aerospace medicine and human performance·2026
Same journal

Long-Term Post-Bariatric Surgical Outcomes for Aeromedical Certification Consideration.

Aerospace medicine and human performance·2026
Same journal

Middle Ear and Sinus Barotraumas of Military Pilots in Finland.

Aerospace medicine and human performance·2026
Same journal

From Humanitarian Airlifts to Neonatal Intensive Care in the Sky.

Aerospace medicine and human performance·2026
Same journal

Cognitive Performance During Acute Hypoxia Is Associated with Cerebral Oxygenation and Blood Flow.

Aerospace medicine and human performance·2026
See all related articles

Related Experiment Video

Updated: Jul 26, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.8K

Spaceflight Recovery Considerations for Acute Inhalational Exposure to Hydrazines.

Brian C Hanshaw, Valerie E Ryder, Benjamin D Johansen

    Aerospace Medicine and Human Performance
    |June 23, 2023
    PubMed
    Summary
    This summary is machine-generated.

    Acute hydrazine exposure in spaceflight primarily risks mucosal and respiratory issues. Neurotoxic or hemotoxic effects are unlikely in the short term, guiding focused clinical treatment for astronauts.

    More Related Videos

    In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells
    04:56

    In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells

    Published on: October 23, 2018

    6.7K
    Safety Precautions and Operating Procedures in an ABSL-4 Laboratory: 3. Aerobiology
    11:13

    Safety Precautions and Operating Procedures in an ABSL-4 Laboratory: 3. Aerobiology

    Published on: October 3, 2016

    14.3K

    Related Experiment Videos

    Last Updated: Jul 26, 2025

    Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
    09:36

    Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

    Published on: September 24, 2020

    2.8K
    In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells
    04:56

    In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells

    Published on: October 23, 2018

    6.7K
    Safety Precautions and Operating Procedures in an ABSL-4 Laboratory: 3. Aerobiology
    11:13

    Safety Precautions and Operating Procedures in an ABSL-4 Laboratory: 3. Aerobiology

    Published on: October 3, 2016

    14.3K

    Area of Science:

    • Aerospace Medicine
    • Toxicology
    • Occupational Health

    Background:

    • Spaceflight operations pose risks from hydrazine and its derivatives.
    • Developing evidence-based guidelines for acute inhalational exposures is critical for crew safety.

    Approach:

    • Conducted a literature review prioritizing human inhalation studies on hydrazine exposure.
    • Included alternative exposure routes and animal studies where human data was limited.

    Key Points:

    • Inhalational hydrazine exposure can cause mucosal irritation and respiratory distress.
    • Neurotoxicity, hepatotoxicity, and hemotoxicity are unlikely in acute, non-recurrent exposures.
    • Longitudinal risks exist but are not the focus of acute management.

    Conclusions:

    • Acute clinical management should prioritize mucosal and respiratory symptoms, including airway management.
    • Limited evidence supports acute interventions for neurotoxicity or hemotoxicity (methemoglobinemia, Heinz bodies).
    • Training should focus on probable acute risks to prevent treatment fixation on unlikely sequelae.